| Literature DB >> 16697705 |
Namal Wijesinghe1, Paul I Thompson, Hugh McAlister.
Abstract
Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16697705 DOI： 10.1016/j.hlc.2006.03.010
Source DB: PubMed Journal: Heart Lung Circ ISSN： 1443-9506 Impact factor: 2.975